# **Nucleotide Metabolism**

Purines and pyrimidines By: Adriana Nudga



# Overview



#### □ Ribonucleotide synthesis

Purine synthesis/degradation: "de novo" and salvage pathwayPyrimidine synthesis/degeneration

Deoxyribonucleotide synthesis





### First a quick review!



### How to remember them



"TUC-TUC around the pyramids"







# **Functions:**

studyaid

- DNA and RNA
- Essential coenzymes:
  - Coenzyme A
  - FAD[H<sub>2</sub>]
  - NAD[H]/NADP[H]
  - cAMP/cGMP
- Energy carriers:
  - ATP
  - GTP

### Step one, the beginning. Creation of PRPP

Important, PRPP is needed for the synthesis of both purines and pyrimidines.

- PRPP is Synthesized from ATP and ribose 5-phosphate
- Catalyzed by PRPP synthetase
- Key substrate in <u>both</u> pyrimidine and purine synthesis







# **Purine synthesis**

Adenine

Guanine

#### "de novo"

This pathway creates nucleotides from scratch.



# QUICK OVERVIEW

" de novo" synthesis is the creation of IMP then IMP turns to Adenine or Guanine.

Rate limiting step is PRPP aminotransferase.

Remember GAG for glutamine, aspartate, and glycine





# Synthesis of IMP for purines

10 step reaction from PRPP to IMP Used :



• 1 PRPP

• 2 glutamine

• 1 Glycine

1 aspartate

• 2 N<sup>10</sup>-formyl-tetrahydrofolate

• 1 HCO<sub>3</sub>[CO<sub>2</sub>]

• 6 ATP





# Step 1: rate limiting step





# GOAL!





#### The 10 step process

- 1. Glutamine:phosphoribosyl pyrophosphate amindotransferase
- 2. GAR synthetase
- 3. Formyltransferase
- 4. Synthetase
- 5. Synthetase
- 6. Carboxylase
- 7. Synthetase
- 8. Adenylsuccinate lyase
- 9. Fromyltrransferase
- 10. Synthase





# Regulation



\*negative feedback inhibition







# Regulation



\*negative feedback inhibition







# **Clinical correlation**

#### 6-Mercaptopurine

- Immunosuppressive drug
- Inhibits PRPP amidotransferase





# **Clinical correlation**

#### Mycophenolic acid

- Immunosuppressive drug
- Inhibits IMP dehydrogenase
- Resulting in  $\downarrow$  GMP production  $\rightarrow \downarrow$  production of T and B cells
- Clinical use: prevent graft rejection



# **Purine synthesis**

#### Salvage pathway

reuse of the performed base resulting from normal cell turnover, or from diet



# QUICK OVERVIEW

Salvage pathway: end products are used to create AMP, IMP, GMP

IMPORTANT ENZYMES: - Adenine phosphorybosyltransferase (APRT)

-Hypoxanthine-guanine phosphorybosyltransferase (HGPRT)





The difference of adenine vs adenosine and guanine vs guanosine is that the "–osine" is attached to the ribose sugar. This is important to distinguish when we start talking about the salvage pathway.





# **Purine degradation**



# QUICK OVERVIEW

- Degradation pathways:
  - IMP -> inosine -> uric acid
  - AMP -> IMP-> inosine -> uric acid
  - Adenosine -> inosine -> uric acid
  - GMP -> guanine -> xanthine -> uric acid
- Majority of URIC ACID is excreted in the urine.
- Purines formed in "de novo" are degraded in the liver. Then free bases are sent to peripheral tissue to join salvage pathway.





During degeneration of nucleotides Free purine and pyrimidine bases (adenine, guanine, ) are released into the cell and are typically transported intercellularly across membranes and salvaged to create more nucleotides via nucleotide salvage. For example, adenine + PRPP --> AMP + PPi.





IMP -> inosine -> uric acid

GMP -> guanine -> xanthine -> uric acid



#### Formation of URIC ACID

```
AMP -> IMP-> inosine -> uric acid
```

```
Adenosine -> inosine -> uric acid
```

The anime group is removed from AMP to form IMP by AMP Deaminase. Or the amine groups is removed from adenosine to form inosine by adenosine deaminase.





# Clinical correlation

Gout

High levels of uric acid in blood (hyperuricemia) -> deposits of monosodium urate(MSU) crystals in joints -> inflamatory response

- Hyperuricemia results primarily from the UNDERexcretion of uric acid.
- OVERproduction of uric acid is rare.





Allopurinol (drug)

- Inhibits Xanthine oxidase
- Gout treatment
- Hypoxanthine analogue
- Inhibits uric acid synthesis
  studuoi

# **Clinical correlation**

#### Lesch-Nyhan syndrome

Salvage pathway

- HGPRT deficiency
- Excess uric acid production and de novo purine synthesis

Hyperuricemia Gout Pissed off (aggression, self mutilation) Retardation DysTonia

# Adenosine deaminase deficie

- ADA deficiency
- One of the major causes of autosomal recessive SCID (severe combined immunedeficiency)
- Excess dATP, resulting in lymphotoxicity







If HGPRT is no functioning then Hypoxanthine and guanine will rise thus pushing for the formation of uric acid



















"de novo"



### **QUICK OVERVIEW**

- The synthesis of any pyrimidine nucleotide begins with the formation of uridine.
- Pyrmidines can be salvaged, however, their high solubility makes pyrimidine salvage less clinically significant than purines.



### Used: 1 PRPP 1 Glutamine 1 Aspartate 1 HCO<sub>3</sub> (CO<sub>2</sub>) 1 NAD<sup>+</sup> 4 ATP





# Carbamoyl phosphate synthetase II

	CPS-I	CPS-II
Location	Mitochondria	Cytosol
Pathway	Urea cycle	Pyrimidine "de novo" synthesis
Regulation	+ N-acetylglutamate	+ PRPP X UTP
Source of nitrogen	ammonia	glutamine



# Step 1 creating carbamoyl phosphate



<u>Gln = glutamine</u> <u>Glu = glutamate</u>



### Step 2: Aspartate transcarbamoylase





# Step 3: Dehydratation







### **Step 4: Oxidation-reduction reaction**







# Step 5: adding PRPP





### Step 6: finally formation of UMP!!!





# Quick overview

 The convertion of uridine to cytidine happens only when UMP is converted to UTP. Only then can CTP be made.



# Nucleotide triphosphate formation

#### $NMP \rightarrow NTP$

- Phosphorylation of NMP to NDP then TTP
- Kinase activity
- Usage: 2 ATP
- The same goes for both purines and pyrimidines

# Gin + H<sub>2</sub>O

 $UTP \rightarrow CTP$ 





# **Clinical correlation**

#### **Ornithine transcarbamoylase** deficiency

- Carbamoyl phosphate availability
- Carbamoyl phosphate leaks out into the cytoplasm
- ↑ pyrimidine synthesis
- Result: Orotic aciduria
- IMPORTANT! NO
- megaloblastic anemia





# **Clinical correlation**

#### **UMP** Synthase deficiency

- ↑ Carbamoyl phosphate availability
- ↑ pyrimidine synthesis
- Result: Orotic aciduria
- IMPORTANT! NO hyperamm









# Quick overview

- dUMP is converted to dTMP by thymidylate synthase.
- It receives a methyl group from N<sup>5</sup>,N<sup>10</sup>-methylene tetrahyfrofolate
- Important pathways to note:
  - One Carbon Metabolism
  - Folate cycle



# Folic acid (vitamin B<sub>9</sub>)

- THF is the active form of folic acid
- Requires 2 NADPH
- Essential enzyme: Dihydrofolate reductase
- A carrier of one-carbon units





### dUMP to dTMP





### Clinical correlations cancer drugs

Methotraxate (MTX)

5 fluorouracil (5-FU)





# **Ribose to deoxyribose**





# What is the difference?





#### Essential enzyme: *Ribonucleotide reductase*

Regulation:

+ ATP

x dATP

x Hydroxyurea anticancer drug Inhibits ribonucleotide reductase





# **GOOD LUCK !!**

